Navigation Links
Phidea Srl and Marvin Research Srl Announce Completion of Merger
Date:1/22/2009

MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a CRO focused on Phase I to Phase IV clinical trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080122/335477 )

The new company will be named Phidea Marvin S.r.l. and have legal and operating offices in Milan, Italy. The combined company will also continue to operate its offices in Madrid, Spain providing drug development services to companies in need of a single source for clinical research including design and management of pan-European clinical trials (Phase I - III), and post marketing studies (Phase IV). Services offered by the new company will include all aspects of the clinical trial process including: protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing. Observational and epidemiological studies will also continue to be performed.

Phidea Marvin specializes in cardiovascular, CNS, gastroenterology oncology, rheumatology and anti-infective studies and services a broad range of multinational pharmaceutical firms.

Vincenzo Cocuzza, M.D., Phidea-Marvin's Chief Executive Officer stated, "We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and especially the United States and will continue to look for strategic opportunities that allow us to realize our goals. The merger with Marvin moves us closer to our objectives by:

    - Adding a partner with a strong market position and reputation in
      specific therapeutic areas

    - Adding additional multinational customers

    - Reducing costs

    - Increasing the overall size of the organization to allow even larger
      studies to be performed.

We also believe that the Marvin and Phidea teams have built an impressive portfolio of accomplishments and will work together to become a leader in the CRO sector."

About Phidea S.r.l.

Phidea S.r.l. specializes in international clinical research. The firm was founded in 1982 in Milan, Italy. In 1991 it expanded its operations and organized its Spanish subsidiary, Phidea Spain, in Madrid, Spain. The firm and partners provide a complete range of services to pharmaceutical companies including product formulation, stability, clinical trial material manufacturing, and all phases of clinical research.

Staffed with renown scientist and medical doctors, Phidea services major pharmaceutical companies seeking premium research in the European Union.

About Marvin Research S.r.l.

Marvin Research was founded in January 1999 by Vincenzo Maresca, M.D., with a team of experts from several CROs. Based in Milan, Italy, the firm focuses on Phase I through Phase IV human clinical trials for multinational pharmaceutical companies. Marvin Research's services span the entire clinical program including preparation of protocols by medical experts, all aspects of monitoring and performance of the trial, and finally statistics and report generation.

    Phidea Marvin Management Team.

    Vincenzo Cocuzza, Chairman and CEO
    Vincenzo Maresca, Managing Director
    Aldo Cocuzza, Managing Director

    For more information regarding Phidea Marvin S.r.l. contact:

    Mr. Aldo Cocuzza, Director,
    +39-3939189389 or email at aldo.cocuzza@phideamarvin.com

    Phidea-Marvin S.r.l.
    International Clinical Research
    Via Cristoforo Colombo, 1.
    Corsico (Milan, Italy)




'/>"/>
SOURCE Phidea Marvin Srl
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
2. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
3. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
4. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
5. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
6. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
7. 2008 Human Research Protection Award Recipients Announced
8. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
9. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
10. Myeloperoxidase Research Expands
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... SAN DIEGO , Oct. 12, 2017 ... has recognized the company with their  2017 New Product Innovation ... is based on extensive primary and secondary medical device market ... AVACEN Medical, through its first-to-market OTC, drug-free pain relief product, ... a unique approach to treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
Breaking Medicine Technology:
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
Breaking Medicine News(10 mins):